Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease
Namita Singh, Marla C. Dubinsky
Springer eBooks (2023), pp. 445-456
Closed Access | Times Cited: 16

Showing 16 citing articles:

A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
M Aardoom, Gigi Veereman, Lissy de Ridder
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 10, pp. 2529-2529
Open Access | Times Cited: 93
Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications
Laura E. Targownik, Eric I. Benchimol, Çharles N. Bernstein, et al.
Journal of Crohn s and Colitis (2020) Vol. 14, Iss. 10, pp. 1354-1363
Closed Access | Times Cited: 51
Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn’s Disease
Ben Kang, So Yoon Choi, Young Ok Choi, et al.
Journal of Crohn s and Colitis (2018) Vol. 13, Iss. 2, pp. 189-197
Open Access | Times Cited: 43
Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease
Karen van Hoeve, Erwin Dreesen, Ilse Hoffman, et al.
Journal of Pediatric Gastroenterology and Nutrition (2019) Vol. 68, Iss. 6, pp. 847-853
Open Access | Times Cited: 41
Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond
Antonello Di Paolo, Giacomo Luci
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 25
Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease
Raffaella Franca, Debora Curci, Marianna Lucafò, et al.
Expert Opinion on Drug Metabolism & Toxicology (2019) Vol. 15, Iss. 7, pp. 527-539
Open Access | Times Cited: 23
Long-Term Outcomes After Drug-Induced Liver Injury
Paul H. Hayashi, Einar S. Björnsson
Current Hepatology Reports (2018) Vol. 17, Iss. 3, pp. 292-299
Open Access | Times Cited: 20
Determination of Serum Infliximab Concentration by Point‐of‐care Devices in Children With Inflammatory Bowel Disease
Debora Curci, Marianna Lucafò, Adriana Cifù, et al.
Journal of Pediatric Gastroenterology and Nutrition (2019) Vol. 69, Iss. 4, pp. 474-479
Open Access | Times Cited: 19
Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
Wenhui Zhang, Astrid Scalori, Franklin Fuh, et al.
Inflammatory Bowel Diseases (2021) Vol. 28, Iss. 9, pp. 1348-1356
Open Access | Times Cited: 9
The Pediatric Inflammatory Bowel Disease Medical Home: A Proposed Model
H Michel, Brendan Boyle, Jennie G. David, et al.
Inflammatory Bowel Diseases (2021) Vol. 28, Iss. 9, pp. 1420-1429
Closed Access | Times Cited: 7
Optimizing Antitumor Necrosis Factor Treatment in Pediatric Inflammatory Bowel Disease With Therapeutic Drug Monitoring
Isabel Pinto Pais, Maria C. Espinheira, Eunice Trindade, et al.
Journal of Pediatric Gastroenterology and Nutrition (2020) Vol. 71, Iss. 1, pp. 12-18
Open Access | Times Cited: 7
Identification of suitable reference microRNA for qPCR analysis in pediatric inflammatory bowel disease
Christie Buonpane, Guillermo Ares, Beshoy Benyamen, et al.
Physiological Genomics (2019) Vol. 51, Iss. 5, pp. 169-175
Open Access | Times Cited: 6
Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
Sara Salvador‐Martín, Alejandra Melgarejo-Ortuño, Luis A. López‐Fernández
Pharmaceutics (2021) Vol. 13, Iss. 11, pp. 1786-1786
Open Access | Times Cited: 6
Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
Ju Young Kim, Yoon Lee, Byung‐Ho Choe, et al.
Gut and Liver (2020) Vol. 15, Iss. 4, pp. 588-598
Open Access | Times Cited: 5
Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases
Juliette Villemonteix, Valérie Guérin‐El Khourouj, Jean‐Pierre Hugot, et al.
Biologicals (2021) Vol. 70, pp. 17-21
Closed Access | Times Cited: 4
Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients
Marieke Zijlstra, M Jongsma, Annick de Vries, et al.
Journal of Pediatric Gastroenterology and Nutrition (2020) Vol. 72, Iss. 1, pp. 56-60
Closed Access | Times Cited: 2
Page 1

Scroll to top